No. | Increased RPE atrophic area (mm2) in treated eyes [Mean (SD)] | P value | |
---|---|---|---|
Age (years) | 0.014* | ||
≦69 | 42 | 1.21 (4.00) | |
70-79 | 34 | 1.72 (3.98) | |
≧80 | 24 | 2.10 (3.97) | |
Gender | 0.671† | ||
Female | 48 | 1.67 (4.25) | |
Male | 52 | 1.71 (4.96) | |
Baseline decimal VA | 0.024* | ||
≧0.5 | 70 | 1.65 (5.08) | |
0.2 - 0.4 | 20 | 2.44 (3.51) | |
≦0.1 | 10 | 3.58 (3.15) | |
PCV lesion area (DA) | 0.001* | ||
≦1 | 29 | 1.34 (3.79) | |
> 1 to ≦2 | 39 | 1.45 (3.88) | |
> 2 to 4 | 17 | 2.08 (3.92) | |
> 4 | 15 | 2.57 (3.94) | |
PED at baseline | 0.576† | ||
No | 68 | 1.58 (4.33) | |
Yes | 32 | 1.83 (4.36) | |
Hemorrhage at baseline | 0.639† | ||
No | 78 | 1.60 (4.15) | |
Yes | 22 | 1.77 (3.85) | |
Area of RPE atrophy at baseline (DA) | 0.003* | ||
Incident | 16 | 0.55 (0.35) | |
Prevalent | 84 | 1.92 (5.47) | |
≦0.5 | 44 | 1.53 (2.95) | |
> 0.5 to 1 | 20 | 2.07 (3.12) | |
> 1 | 20 | 2.59 (3.92) | |
Area of RPE atrophy in fellow eye at baseline (DA) | 0.967* | ||
≦0.5 | 39 | 1.55 (3.41) | |
> 0.5 | 61 | 1.77 (4.07) | |
Location of PCV lesion | 0.928† | ||
Subfoveal | 88 | 1.70 (5.24) | |
Not subfoveal | 12 | 1.65 (3.95) | |
Intraretinal fluid at baseline | 0.657‡ | ||
None | 11 | 1.73 (3.46) | |
Not subfoveal | 6 | 2.08 (2.15) | |
Subfovea | 83 | 1.67 (4.64) | |
Subretinal fluid at baseline | 0.687‡ | ||
None | 76 | 1.67 (3.31) | |
Not subfoveal | 6 | 1.72 (3.62) | |
Subfovea | 18 | 1.86 (3.93) | |
Number of IVR during 3-year follow-up period | 0.336* | ||
1-5 | 8 | 1.69 (2.71) | |
6-10 | 36 | 1.68 (3.86) | |
11-15 | 42 | 1.70 (4.25) | |
≧16 | 14 | 1.66 (2.25) | |
Polypoidal lesions three years after the first IVR | 0.871† | ||
Detection | 78 | 1.68 (4.45) | |
No detection | 22 | 1.72 (4.73) | |
Decimal VA three years after the first IVR | 0.016* | ||
≧0.5 | 78 | 1.39 (4.83) | |
0.2 - 0.4 | 15 | 2.44 (3.86) | |
≦0.1 | 7 | 3.31 (2.29) |